ArticleFrontiers in microbiology2025
Hesperidin alleviated D-GalN/LPS induced acute liver injury in mice: insights into gut microbiota and the Nrf2/Keap1 pathway.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute liver injury (ALI) has grown to be a major worldwide health issue, yet current therapeutic approaches remain inadequate. A growing number of studies suggest that hesperidin demonstrates high therapeutic potential in the treatment of acute liver injury. However, the specific mechanisms by which hesperidin alleviates ALI remain unclear. Herein, we aimed to investigate how hesperidin ameliorates acute liver injury under conditions that influence the gut microbiota. Methods: A mouse model of ALI was established by D-GalN/LPS injection, and 16S rDNA sequencing was employed to explore the underlying mechanism of hesperidin in alleviating ALI. Forty mice were divided into the control group (CON), the LPS&D-GalN group (ALI), the HDN group (feed hesperidin), the HDA group (the positive drug group, feed hesperidin). Liver, ileum, and serum samples were collected randomly from five mice in each of the four groups to evaluate liver injury markers, inflammatory indicators, intestinal barrier function indices, and antioxidant parameters. Additionally, cecum contents were collected for 16S rDNA sequencing to analyze the gut microbiota. Results: Hesperidin significantly ameliorated D-GalN/LPS-induced abnormal transaminase activities, liver and intestinal systemic inflammation, and intestinal environmental disorders. Furthermore, activation of the Nrf2/Keap1 signal pathway by HDN reduced the production of proinflammatory cytokines (TNF-α, IL-1β and IL-6) and boost the activity of antioxidant enzymes (CAT and SOD). HDN restored SCFAs to normal levels by upregulating the abundance of beneficial bacteria (Lachnospiraceae_NK4A136_group, Conclusion: Hesperidin as a promising natural compound capable of modulating the gut-liver axis and strengthening endogenous antioxidant mechanisms, providing valuable insight into its potential therapeutic application in acute liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.